Direct answer: Start by identifying which stage and type best describes the company (clinical-stage, commercial-stage, platform, gene/cell therapy, or diagnostics/tools), then apply the corresponding research framework. The single most important question varies by type: cash runway and next catalyst for clinical-stage, product revenue trajectory for commercial-stage, and platform validation breadth for platform companies.
How to Research Nasdaq Biotechnology Index Companies
Why biotech research requires stage-specific frameworks
The Nasdaq Biotechnology Index spans companies at very different stages of development, from pre-revenue clinical-stage biotechs burning cash to reach a first approval, to large-cap pharmaceutical companies with mature marketed products, global commercial organizations, and patent cliffs to manage.
A single research checklist cannot serve all of them. Applying traditional revenue multiples and earnings growth analysis to a clinical-stage company with no revenue produces meaningless numbers. Conversely, evaluating a large commercial biopharma purely on pipeline probability ignores the revenue streams that actually drive its valuation.
The practical starting point is company classification: which stage and type best fits this company today? That classification determines which questions to ask first and which metrics to weight most heavily. This guide provides a framework for each major type found in the NBI.
Clinical-stage companies
Clinical-stage companies have no approved product and depend on clinical trial outcomes for value creation. Their research framework starts with the pipeline and works outward:
Lead asset
Identify the lead drug candidate. What is its target, biology, and the disease indication it is addressing? For companies with multiple assets, which program represents the largest fraction of expected value and when is the next significant readout?
Trial design and endpoints
Understand the trial design: phase, comparator arm, primary and secondary endpoints, enrollment targets, and expected timeline. Primary endpoints determine whether the drug will pass regulatory review, not just whether it shows a biological effect. A trial powered to show statistical significance on a surrogate endpoint that regulators have not previously accepted as a basis for approval carries regulatory risk beyond the efficacy probability.
Human efficacy and safety data
Any existing human data, even from early-phase trials, is more informative than preclinical data. Look for proof-of-concept data from Phase 1 or Phase 1b trials. Absence of human data at all is a much earlier stage of risk than Phase 2 data showing efficacy but with an unclear safety profile.
Next catalyst and cash runway
Identify the next major value-defining event (data readout, regulatory decision, partnership announcement) and its expected timing. Then determine how much cash the company has and at what burn rate. The question is whether the company can reach that catalyst without requiring a new equity raise. A raise before a major catalyst typically dilutes existing shareholders and signals the company believes the catalyst alone will not sustain the stock.
Dilution history and risk
Review the company's history of equity raises. Frequent large raises at decreasing prices signal that the pipeline is consuming capital faster than expected. The dilution risk is not just about current cash; it is about whether the company can survive to reach a meaningful proof-of-concept event without a damaging capital structure.
Commercial-stage companies
Commercial-stage companies have at least one marketed product. The research framework shifts from probability analysis to revenue quality and sustainability:
Product-level revenue
Analyze revenue at the product level, not just the company level. Which product lines are growing, which are stable, and which are declining? A company with three marketed products may have one strong grower, one mature plateau, and one declining because of competition or patent expiry. Blended revenue growth conceals this composition.
Demand, volume, and net pricing
Decompose revenue growth into volume and price. Pricing power is harder to sustain in competitive categories and under increasing payer pressure. Volume growth driven by geographic expansion or label expansions is generally more durable than price increases. Net pricing (after rebates, discounts, and payer adjustments) is the number that matters, not gross list price.
Payer access and market share
For a commercial product, payer coverage and formulary access determine how widely physicians can actually prescribe it. Restricted formulary access, prior authorization requirements, or step therapy requirements can cap adoption even for a clinically superior drug. Track payer dynamics as a leading indicator of future revenue.
Patent life and exclusivity
Identify each product's primary patent expiry and any regulatory exclusivity periods (orphan designation, data exclusivity, pediatric exclusivity). Approaching patent cliffs create revenue risk. Biosimilar competition is particularly disruptive for biologic products where multiple biosimilars may enter the market over a few years following loss of exclusivity.
Free cash flow and pipeline replacement
Mature commercial biotechs should be evaluated on free cash flow generation. The pipeline replacement question is whether the company is investing enough in next-generation products to offset revenue at risk from patent expirations.
Platform companies
Platform companies are built around a technological capability (mRNA, CRISPR, RNAi, protein degradation, antibody-drug conjugates) that they intend to deploy across multiple disease areas. Their research framework adds a platform validation question on top of individual asset analysis:
Platform validation in humans
The core question is whether the platform has been demonstrated in humans, not just in preclinical models. Preclinical success does not reliably predict human translation, especially for novel modalities. One successful human program is evidence; multiple successful human programs from the same platform are stronger validation. A platform whose programs have all failed in human trials is not validated regardless of the preclinical data.
Diversified partner economics
Platform companies often license their technology to pharmaceutical partners. Partnership economics (upfront payments, milestone structures, royalty rates) provide an alternative signal of the platform's perceived value. A platform that large pharmaceutical companies are willing to pay substantial milestones to access has external validation beyond Swoopr's own assessment.
Program breadth and diversification
A platform with five programs in different disease areas has diversified binary risk compared to a single-asset company. But only if each program has genuinely independent biology. Programs that all depend on the same delivery mechanism or target class are correlated, not independent.
Gene and cell therapy companies
Gene and cell therapy companies apply the standard clinical-stage framework but require additional evaluation of modality-specific factors:
Delivery mechanism
How does the therapy reach the target tissue? Adeno-associated virus (AAV), lentiviral vector, lipid nanoparticle, and ex vivo cell modification each have different tissue tropism profiles, immunogenicity risks, and re-dosing limitations. AAV vectors, for instance, cannot typically be re-administered due to pre-existing or developed antibodies. Evaluate whether the delivery mechanism suits the indication and disease course.
Durability of effect
One of the central unknowns in gene therapy is how long the effect persists. Early clinical data may show strong initial responses; long-term follow-up data (2-5+ years) is required to assess whether durability matches the therapeutic promise. "Durable" in preclinical models does not translate reliably to human patients.
Manufacturing and CMC
Gene and cell therapies are among the most complex biologics to manufacture. Chemistry, manufacturing, and controls (CMC) challenges are a common cause of regulatory delays even when efficacy and safety data are favorable. Assess whether the company has credible commercial-scale manufacturing either internally or through a contract manufacturer.
Treatment center capacity
Many gene and cell therapies require administration at specialized treatment centers with specific infrastructure. Market penetration is limited by the number of certified centers, especially at launch. A therapy with strong efficacy data but only 20 certified treatment centers in the United States will not generate commercial-scale revenue quickly.
Diagnostics and tools companies
Some NBI constituents are primarily diagnostics or life science tools companies that are classified under ICB Biotechnology because a portion of their business involves therapeutic programs. Their research framework adds operational metrics from the instruments or diagnostics industry:
Installed base and pull-through
For instrument-based businesses (sequencing platforms, flow cytometers, PCR systems), the installed base is the key asset. Instruments generate recurring consumables revenue at high margins. Evaluate both the size of the installed base and the pull-through rate (consumables revenue per instrument per year), which is the more reliable indicator of utilization.
Test and sample volumes
For diagnostics companies, volume growth in tests or samples processed is the operating metric most closely tied to near-term revenue. Mix shifts between higher and lower value tests affect revenue even when volumes are stable.
Reimbursement and research funding
Diagnostics depend on reimbursement coverage from CMS and commercial payers for clinical tests, and on NIH and foundation grant levels for research tools. Both funding streams are outside the company's direct control and can shift meaningfully.
FAQs
Why does the research approach differ by biotech company stage?
Because the sources of value and risk are fundamentally different. A clinical-stage company with no revenue is valued on pipeline probability and cash runway. A commercial-stage company is valued on product revenue, pricing power, and patent life. Applying commercial-stage financial metrics to a pre-revenue biotech, or vice versa, produces misleading conclusions.
What is the most important question for a clinical-stage biotech?
Cash runway relative to the next major clinical catalyst. A company with 18 months of runway approaching a pivotal Phase 3 readout is in a very different position from one with the same runway and no near-term catalysts. The combination of catalyst timing, runway, and dilution risk determines how an investor frames position sizing.
What is the main risk difference between platform and asset-focused biotechs?
A single-asset company succeeds or fails with that asset. A platform company has diversified program risk but faces the challenge of proving the platform's generalizability. Platform validation requires evidence across multiple programs in humans, not just in preclinical models. Until multiple human programs succeed, the platform's breadth is a thesis, not a fact.
What additional factors matter for gene and cell therapy companies?
Beyond the standard clinical research framework, gene and cell therapy requires evaluating delivery mechanism, durability of effect in long-term follow-up, manufacturing and CMC challenges at scale, and treatment center infrastructure. A curative therapy that cannot be delivered reliably at commercial scale has limited investment value regardless of efficacy data.